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Chrysanthemum indicum L. (CIL) is widely used as an anti-inﬂammatory agent in Asia and our preliminary study revealed that
CIL reduced interleukin (IL)-4 and IL-13 in 2,4-dinitrochlorobenzene (DNCB)-treated HaCaT cells, a human keratinocyte cell
line. We investigated the atopic dermatitis (AD) eﬀect of topically applied CIL in mice with AD-like symptoms. After topical
application of 1,3-butylen glycol (control), CIL-Low (5%), CIL-High (30%), or 0.1% hydrocortisone (HC) on the AD-like skin
lesions in DNCB-treated NC/Nga mice for 5 weeks, the ear thickness, mast cell inﬁltration, and serum immunoglobulin E (IgE),
IgG1, IL-4 and interferon (IFN)-γ were measured. The gene expressions of IL-4, IL-13, and IFN-γ in the dorsal skin were assayed.
CIL treatment dosedependently reduced severity of clinical symptoms of dorsal skin, ear thickness, and the number of mast cells
and eosinophils. CIL-High signiﬁcantly decreased serum IgE, IgG1, IL-4, and IFN-γ levels and reduced mRNA levels of IFN-γ,
IL-4, and IL-13 in dorsal skin lesion. The improvement by CIL-High was similar to HC, but without its adverse eﬀects such as skin
atrophy maceration, and secondary infection. In conclusion, CIL may be an eﬀective alternative substance for the management of
AD.
1.Introduction
Atopic dermatitis (AD) is a common skin disease charac-
terized by chronic and relapsing inﬂammatory dermatitis
with immunological disturbances [1]. The incidence of AD
is continuously increasing worldwide with a prevalence rate
of approximately 10–20% and is more common among
infants and children. Most patients with AD have increased
circulating eosinophils and immunoglobulin (Ig) E due to
elevated interleukin (IL)-4, IL-5, and IL-13 produced by T-
helper (Th) 2 cells [2, 3]. Th2 immune responses are known
to play an important role in the pathogenic mechanism of
AD.Inaddition, Th1immuneresponserelatedtointerferon-
gamma (IFN-γ) is also associated with the pathophysiology
ofAD.Therefore,ADisknowntobeabiphasicinﬂammatory
skin disease, provoked by Th1/Th2 immune responses [4].
Acute AD skin lesions exhibit Th2 type inﬂammatory
cytokine proﬁles, whereas the chronic phase is characterized
by Th1 type immune responses releasing Th1 cytokines such
as IFN-γ and IL-12 and delayed-type hypersensitivity reac-
tions[4,5].TheimbalanceofTh1andTh2immunerespons-
es plays important roles in the development of AD [6, 7].
NC/Nga mice are the most extensively studied animal
model of AD since the inbred strain was established in 1957
[8]. These mice spontaneously develop AD-like eczematous
skin lesions when kept in air-uncontrolled conventional
housing, but not when maintained under speciﬁc pathogen-
free (SPF) conditions [8]. However, when these mice are
maintained under conventional conditions, the low inci-
denceofAD-likelesionsisadrawback[8].Incontrast,chem-
ical hapten, 2,4-dinitroﬂuorobenzene (DNFB), or 2,4-
dinitrochlorobenzene (DNCB) application produces 100%2 Evidence-Based Complementary and Alternative Medicine
reproducible AD-like lesions in NC/Nga mice [8–10]. Both
DNCB- and DNFB-induced contact hypersensitivity is a T-
cell-mediated inﬂammatory skin reaction that is believed to
be associated with Th1 activation [11, 12]. Since the clin-
ical symptoms displayed in the NC/Nga mice treated with
chemicals and humans with AD are similar, the mice are
considered to be AD animal model suitable for understand-
ing and evaluating eﬀective therapeutic strategies for AD
[8]. Since topical hydrocortisone exerts anti-inﬂammatory,
antipruritic, and vasoconstrictive actions, it is widely ac-
cepted that topical hydrocortisone therapy is crucial for the
management of AD. However, it cannot be used for long
periods, and adverse side eﬀects are frequently observed
likeburning,itching,irritation,dryness,folliculitis,hypertri-
chosis, acneiform eruptions, hypopigmentation, perioral
dermatitis, allergic contact dermatitis, maceration of the
skin, secondary infection, skin atrophy, and striae.
Accordingly, a wide variety of natural products are cur-
rently being evaluated for alternative AD therapies, with the
ideal agent possessing potent eﬃcacy with a minimal side
eﬀectproﬁle[10,13,14].ChrysanthemumindicumL.iswide-
ly used for anti-inﬂammatory agents in Southeast Asian folk
medicine. It was also found to have anti-microbial, anti-
oxidant, and anti-inﬂammatory action [15, 16]. Chrysanthe-
mum indicum L. inhibits inﬂammatory mediators, such as
NO, PGE2,T N F - α,a n dI L - 1 β, via suppression of MAPKs
and NF-κB-dependent pathways [15]. In addition, our pre-
liminary study revealed that the 1,3-butylene glycol extract
of dried ﬂowers of Chrysanthemum indicum L.d e c r e a s e s
the expression of IL-4 and IL-13 the most in DNCB-treated
HaCaT cells, human keratinocytes, when the extracts of
23 herbs including Chrysanthemum indicum L.w e r ec o m -
pared. These eﬀects may be due to the sesquiterpene com-
pounds such as kikkanol A, B, and C and ﬂavone gly-
cones such as eriodictyol 7-O-β-D-glucopyranosiduronic
acid, acaciin, and luteolin 7-O-β-D-glucopyranoside [17,
18]. Thus, Chrysanthemum indicum L. may relieve AD-like
symptoms. However, it has not yet been determined whether
Chrysanthemum indicum L. suppresses the development and
progression of AD. In this study, we used the DNCB-treated
NC/Nga murine model to examine the inhibitory eﬀect
of Chrysanthemum indicum L. on the development and
progression of AD-like skin lesions.
2.MaterialsandMethod
2.1. Preparation of Chrysanthemum indicum L. Extracts.
Dried ﬂowers of Chrysanthemum indicum L. were purchased
in Kyung-Dong Herb market (Seoul, Korea) in 2008, iden-
tiﬁed by Dr. Joo YS (Department of Herbology, Woosuk
University, Wanju-gun, Korea), and a voucher specimen
(No. 2008-05 and 2008-06) deposited at the herbarium of
Department of Food & Nutrition, Hoseo University. Since
1,3-butylene glycol is a good solvent for making skin lotion,
dried ﬂowers of Chrysanthemum indicum L. (1kg) were
extracted at room temperature for 12 hours with 20 or 3.3
L of 1,3-butylene glycol, ﬁltered, and the ﬁltrates centrifuged
at 450×g to make 5 or 30% extracts. When more than 30%
Chrysanthemum indicum L. was extracted with 1,3-butylene
glycol, the extract formed a precipitate. The supernatants
were used for topical application.
2.2. Animals. Twenty female 6-week-old NC/Nga mice were
purchased from Charles River Japan (Yokohama, Japan) and
maintained under conventional conditions: a 12h light/12h
dark cycle, room temperature of 22-23◦C, and humidity of
55 ± 15%. The mice had free access to food and water.
A l ls u r g i c a la n de x p e r i m e n t a lp r o c e d u r e sw e r ep e r f o r m e d
according to the guidelines of the Animal Care and Use
Review Committee at Hoseo University, Korea.
2.3. Induction of AD-Like Skin Lesion. Mice were anes-
thetized with a mixture of ketamine and xylazine (100 and
10mg/kg body weight), after which the animal’s back hair
and right ear were shaved 1 day prior to sensitization. In the
ﬁrst day, 1% DNCB in acetone/olive oil (3:1) was applied to
the dorsal skin and right ear then 0.2% DNCB was applied
every other day [19]. The same volume of acetone/olive oil
vehicle was applied instead of DNCB solution to controls.
2.4. Topical Application of 1,3-Butylene Glycol Extracts of
Chrysanthemum indicum L. To determine the AD eﬀect
of Chrysanthemum indicum L., two dosages were assigned
based on the preliminary cell-based study and the maximum
dosage to extract. A preliminary study showed that 50μg/mL
of Chrysanthemum indicum L. was eﬀective against an AD
model in HaCaT cells, a human keratinocyte cell line, but
not 5μg/mL. After the induction of the AD-like skin lesions,
animals were divided into four groups of 10 mice each.
These groups were then treated topically in the dorsal skin
and right ear for 5 weeks with one of four agents: 1,3-
butylene glycol (BG; control), 5 or 30% dried ﬂower of
ChrysanthemumindicumL.(CIL-LoworCIL-High),or0.1%
hydrocortisone butyrate (HC; positive control) twice a day.
Mice with no induction of AD-like skin lesion were treated
with 1,3-butylene glycol as a normal control.
2.5.EvaluationofSkinLesionSeverity. Therelativedermatitis
severity was assessed macroscopically using the following
scoring procedure. The total skin severity score was deﬁned
as the sum of the individual scores for each of the following
four signs: (1) erythema and hemorrhage, (2) edema, (3)
erosion (excoriation), and (4) scaling (dryness) [20]. In
this system, 0 was deﬁned as exhibiting no symptoms, 1 as
mild symptoms, 2 as moderate symptoms, and 3 as severe
symptoms. Additionally, the mice were photographed once
per week.
Ear thickness was measured before and after induction of
the inﬂammatory response using a digital micrometer (MSI-
Viking, Duncan, SC). The micrometer was applied near the
tip of the ear just distal to the cartilaginous ridges, and
the thickness was recorded in micrometers. To minimize
technique variations, a single investigator performed the
measurements throughout each experiment.
2.6. Measurement of Serum IgG1 and IgE Levels and
Iterleukin-4 (IL-4) and Interferon-γ (IFN-γ)C y t o k i n eL e v e l s .
The total serum IgG1 and IgE was quantiﬁed by sandwichEvidence-Based Complementary and Alternative Medicine 3
enzyme-linked immunosorbent assay (ELISA) Quantitation
Kit (R&D Systems, Minneapolis, MN, USA) according to
the manufacturer’s protocol. The serum concentrations of
the cytokines (IL-4 and IFN-γ) were also quantiﬁed using a
mouse cytokine enzyme immunoassay kit (R&D Systems).
2.7. Real-Time Quantitative Reverse Transcriptase-Polymerase
Chain Reaction (RT-PCR). The dorsal skin tissues from ﬁve
mice from each group were collected at the end of treat-
ment. Total RNA was isolated from the skin tissues using
a monophasic solution of phenol and guanidine isothiocy-
anate (Trizol reagent, Gibco-BRL, Rockville, MD), followed
by extraction and precipitation with isopropyl alcohol. The
cDNA was synthesized from equal amounts of total RNA
with superscript III reverse transcriptase, and polymerase
chain reaction (PCR) was performed with high-ﬁdelity Taq
DNA polymerase. Equal amounts of cDNA were mixed
with SYBR Green supermix (Bio-Rad) mix and were ana-
lyzed using a realtime PCR machine (BioRad Laboratories,
Hercules, CA). The expression level of the gene of interest
was corrected for that of the house keeping gene, β-actin.
The following primers were used for PCR reactions (5 -3 ),
mouse IFN-γ, sense 5 -CGGCACAGTCATTGAAAGCCTA-
3 , and antisense 5 -GTTGCTGATGGCCTGATTGTC-
3 ;I L - 4 ,s e n s e5  -TCTCGAATGTACCAGGAGCCATATC-
3 , and antisense 5 -AGCACCTTGGAAGCCCTACAGA-
3 ; mouse IL-13, sense 5 -cagctccctggttctctcac-3 ,a n da n t i -
sense 5 -ccacactccataccatgctg-3 ;m o u s eβ-actin, sense 5 -
CATCCGTAAAGACCTCTATGCCAAC-3 , and antisense 5 -
ATGGAGCCACCGATCCACA-3 . The primers were de-
signed to sandwich at least one intron in order to distinguish
between the products derived from mRNA and genomic
DNA.
2.8. Histological Analysis. Dorsal samples were taken 24h
after ﬁnal DNCB administration on day 35 and they were
ﬁxed in 10% buﬀered neutral formaldehyde and embedded
in paraﬃnw a x .H i s t o l o g i c a ls e c t i o n sw e r e6 μm thick and
were stained with haematoxylin and eosin for counting
number of eosinophils. The sections were also stained with
0.5% toluidine blue for investigating the number of mast
c e l l s .T h ec e l lc o u n t sw e r ep e r f o r m e di ns i xc o n s e c u t i v e
microscopic ﬁelds at 400x magniﬁcation.
2.9. Statistical Analysis. Statistical analysis was performed
using SAS software and all results expressed as
mean ± standard deviation. The biological and metabolic
eﬀects of CIL-Low, CIL-High, HC (positive control), and
v e h i c l e( an e g a t i v ec o n t r o l )w e r ec o m p a r e db yo n e - w a y
ANOVA. Signiﬁcant diﬀerences in the main eﬀects among
thegroupswereidentiﬁedbyTukey’stestatP<0.05.Thesig-
niﬁcance of diﬀerences between the mice with and without
AD-like skin lesion was determined by two-sample t test.
3. Results
3.1. Severity of Skin Lesion. T h eN C / N g am i c ed e v e l o p e d
AD-likeskinlesionsfollowingrepeatedapplicationofDNCB
as evidenced by skin lesion scores, whereas normal controls
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Figure 1: Changes in severity scores and ear thickness of atopic
dermatitis (AD) in NC/Nga mice. AD was induced in Nc/Nga
mice by topical application of 2,4-dinitrochlorobenzene (DNCB)
in the dorsal skin, and a right ear was topically treated with 1,3-
butylenglycol(BG;control),5%ChrysanthemumindicumL.(CIL-
Low), 30% Chrysanthemum indicum L. (CIL-High), and 0.1%
hydrocortisone (HC) on the lesions for 5 weeks. Normal controls
did not have DCNB-induced AD. CIL decreased clinical severity of
atopic dermatitis symptoms and ear thickness in a dose-dependent
manner, and CIL-High had a statistically similar eﬀect on the
severity as HC. (a) Changes in severity scores. (b) Changes of ear
thickness. Each value represents the mean ± SD of 10 mice in each
group. ∗Signiﬁcantly diﬀerent among the diﬀerent treatments in
Nc/Nga mice at P<0.05. a, b, c Values with diﬀerent superscripts
were signiﬁcantly diﬀerent among Nc/Nga mice by Tukey test at
P<0.05. †Signiﬁcantly diﬀerent between control (BG) and normal
control at P<0.05.
did not exhibit any skin lesions. The total scores were
calculated from sums of the scores for erythema, edema,
erosion, and dryness; with a score of 12 indicating the most
severe state. The normal controls exhibited no changes in
skin lesion scoresover time (Figure 1(a)).Inaccordancewith
thepreviousﬁnding,theclinicalseverityofskinlesionsinthe
control group increased gradually depending on the times of
challenge with DNCB. All mice in the control group treated
with BG (control) exhibited AD-like skin lesions including
erythema, edema, erosion, and dryness in the dorsal skin
(Figure 1(a)). However, topical application of CIL dose-
dependently lowered the skin lesion scores below that of the
controls: CIL-Low signiﬁcantly decreased the clinical scores4 Evidence-Based Complementary and Alternative Medicine
at4and 5weeks fromthe DNCB sensitization in comparison
to the control, and CIL-High lowered the scores more than
CIL-Low (Figure 1(a)). The decreased clinical scores in CIL-
High were similar to those observed with HC treatment.
These results indicated that CIL-Low and CIL-High reduced
the progression of AD-like skin lesions in comparison to the
control, and CIL-High exhibited the similar improvement
to HC. The scores increased after topical application and
began to be lowered from day 21 in CIL-Low and CIL-High,
whereas they reached a maximum at day 28 in the BG group
(Figure 1(a)).
3.2. Ear Thickness. Ear thickness gradually increased after
topical application of DNCB in BG and CIL-Low groups up
to the 4th week but in CIL-High and HC groups, only up to
the3rdweek(Figure 1(b)).ThisindicatedthattheADsymp-
toms were alleviated after the peak of ear thickness. Ear
thickness in the CIL-Low group signiﬁcantly lowered only
at the 4th week while CIL-High suppressed its increase in
comparison to the BG group from the 2nd week of sen-
sitization (Figure 1(b)). Ear thickness of the CIL-Low and
CIL-High groups was signiﬁcantly diﬀerent at the 4th and
5th weeks. The decrease in the CIL-High group was not sig-
niﬁcantly diﬀerent from HC (Figure 1(b)). Ear thickness did
not change in the normal control group during the exper-
imental periods.
3.3. Serum IgG1, IgE, IL-4, and INF-γ Levels. At day 35 after
the sensitization, serum IgG1 and IgE levels were higher in
the control group than in the normal control group, but the
levels were dosedependently reduced by CIL treatments in
DNCB-treated mice (Figure 2(a)). CIL-Low and CIL-High
decreased circulating levels of IgG1 and IgE, but it was
statistically signiﬁcant only for CIL-High which had levels
close to those of HC. IL-4 produced by Th2 cells was much
greater in the control group than the normal control group
whereas only CIL-High signiﬁcantly suppressed the increase
in DNCB-treated mice, and the suppression was as much as
in HC, a positive control (Figure 2(b)). The control group
also exhibited higher levels of INF-γ produced by Th1 cells
than the normal control group, but CIL-High lowered the
levels in DNCB-treated mice, but it did not reach levels of
the normal control group (Figure 2(b)). The reduction of
serum INF-γ levels was statistically similar to HC. The ratio
of IL-4 and IFN-γ was higher in control group than normal
control, whereas the ratio was dosedependently lowered by
CIL in DNCB-treated mice, but only CIL-High signiﬁcantly
decreasedtheratio.Theratiowasstatisticallysimilarbetween
CIL-High and HC (data not shown).
3.4.HistologicalFindingsandMastCellCountsintheInﬂamed
Skin. The dorsal skin of the mice in the control groups
exhibited hypertrophy, hyperkeratosis, intercellular edema,
the liquefaction degeneration of the basal layer, and inﬁltra-
tion of inﬂammatory cells such as mast cells and eosinophils
in contrast to the normal control group (Figure 3). The
symptoms seen in dorsal skin such as hypertrophy, hyper-
keratosis, intercellular edema, and liquefaction degeneration
of the basal layer were relieved by the treatments with CIL
a
ab
c
bc
a
ab
c bc
0
1000
2000
3000
4000
5000
6000
IgE (ng/mL) IgG1 (μg/mL)
†
†
(a)
a
ab
bc
a a b
0
20
40
60
80
100
120
140
160
180
IL-4 (pg/mL) IFN-γ (ng/mL)
BG HC
Normal control CIL-low
CIL-high
c∗
b∗
†
†
(b)
Figure 2: Serum levels of IgG1, IgE, IL-4, and IFN-γ levels at
the end of experimental periods. AD was induced in Nc/Nga
mice by topical application of 2,4-dinitrochlorobenzene (DNCB)
in the dorsal skin, and a right ear was topically treated with
1,3-butylen glycol (BG; control), 5% Chrysanthemum indicum L.
(CIL-Low), 30% Chrysanthemum indicum L. (CIL-High), and 0.1%
hydrocortisone (HC) on the lesions for 5 weeks. Normal controls
did not have DCNB-induced AD. After 5 weeks of treatments,
serum was separated to measure immunoglobulins and cytokines.
CIL-High signiﬁcantly reduced circulating levels of cytokines and
immunoglobulins in comparison to the control, and CIL-High
exhibited a statistically similar amelioration to HC. (a) Serum levels
of IgG1 and IgE. (b) Serum levels of IL-4 and INF-γ.E a c hv a l u e
represents the mean ± SD of 10 mice in each group. ∗Signiﬁcantly
diﬀerent among the diﬀerent treatments in Nc/Nga mice at P<
0.05. a, b, c Means on the bars with diﬀerent superscripts were
signiﬁcantlydiﬀerentamongNc/NgamicebyTukeytestatP<0.05.
†Signiﬁcantly diﬀerent between control (BG) and normal control at
P<0.05.
in a dose-dependent manner. As seen in Figure 3(a),h y p e r -
trophy, hyperkeratosis, intercellular edema, and liquefaction
degeneration of the basal layer were ameliorated with CIL-
Low and CIL-High treatment in comparison to the control
group (Figure 3(a)). The improvement of the symptoms in
CIL-High was similar to the improvements in the HC group.
An increased number of mast cells and eosinophils were
observed in the skin lesions of the control group compared
to the normal control group (Figures 3(a) and 3(b)).
The increase in mast cell and eosinophil counts was dose
dependently suppressed by CIL treatment in DNCB-treatedEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: The number of mast cells and eosinophils of the dorsal skin with histopathological analysis. AD induced in Nc/Nga mice by
topical application of 2,4-dinitrochlorobenzene (DNCB) in the dorsal skin, and a right ear was topically treated with 1,3-butylen glycol
(BG; control), 5% Chrysanthemum indicum L. (CIL-Low), 30% Chrysanthemum indicum L. (CIL-High), and 0.1% hydrocortisone (HC) on
the lesions for 5 weeks. Normal controls did not have DCNB-induced AD. After 5 weeks of treatments, the dorsal skin was ﬁxed with 10%
formaldehyde, embedded in paraﬃn, and then sections were made. The skin sections were stained with hematoxylin and eosin and toluidine
blue staining. CIL-High signiﬁcantly elevated mast cells and eosinophils in the lesion of the dorsal skin in comparison to the control and
exhibitedastatisticallysimilarincrementtoHC.Eachvaluerepresentsthemean ±SDof5miceineachgroup.(a)Thenumberofeosinophils
as determined by hematoxylin and eosin staining. Eosinophils exhibited as blue dots. (b) The number of mast cells determined by toluidine
blue staining. Mast cells appear as blue dots. ∗Signiﬁcantly diﬀerent among the diﬀerent treatments in Nc/Nga mice at P<0.05. a, b, c
Means on the bars with diﬀerent superscripts were signiﬁcantly diﬀerent by Tukey test at P<0.05. †Signiﬁcantly diﬀerent between control
(BG) and normal control at P<0.05.
mice. CIL-Low decreased the mast cells and eosinophils
in comparison to the control, but it was not signiﬁcantly
diﬀerent. CIL-High signiﬁcantly lowered them, and the
decreasewassimilartotheHCgroup(Figures3(a)and3(b)).
3.5. Cytokine mRNA Expression Levels. To determine cytok-
ine production in the inﬂamed dorsal skin lesions, mRNA
expression of IL-4, IL-13, and INF-γ cytokines was analyzed.
The dorsal skin tissues of DNCB-treated control mice
exhibited much higher expression levels of IL-4, IL-13,
and IFN-γ than those of the normal controls (Figure 4).
CIL suppressed the mRNA expression of IL-4 and IL-13
produced by Th2 cells in a dose-dependent manner, while
theexpressionofIFN-γ producedbyTh1wasalsoreducedby
CIL treatment (Figure 4). However, the decreases in mRNA
levels were signiﬁcantly diﬀerent only in CIL-High, not in
CIL-Low, and the reduction of INF-γ was less than that
of IL-4 and IL-13 in CIL treatment. The decreased expres-
sions of IL-4, IL-13, and IFN-γ by CIL-High were similar
to those following treatment with HC, a positive control
(Figure 4).
4. Discussion
Atopic dermatitis is a biphasic inﬂammatory skin disease,
provoked by an imbalance between Th1 and Th2 immune
responses [4]. Th2 immune responses are mediated by
interleukin (IL)-4, IL-5, and IL-13 while Th1 immune
responses are modulated by IFN-γ [2]. In particular, Th2
responses are key elements to the pathogenesis of atopic
disorders. NC/Nga mice were the ﬁrst mouse model of AD
reported by Matsuda et al. [21], and the mice treated with
DFBN, DNCB, or picryl chloride have also been used as an
animal model for human AD [22]. Elevated levels of serum
total IgE have been reported to correlate with the appearance
of the AD-like lesions in NC/Nga mice, with massive
inﬁltration of IL-4- and IL-13-producing Th2 cells and the
degranulation of mast cells and eosinophils [4]. HC is a
potent topical corticosteroid used to alleviate rash, eczema,
anddermatitis.However,HCisasteroidalagentwithadverse
eﬀects such as facial hypertrichosis, folliculitis, miliaria, and
genital ulcers [23], which has inspired to investigations of
nonsteroidalagentsforrelievingAD.Recently,severalstudies
have reported that Herbal Oriental Medicine therapy may
be eﬀective in AD patients [24]. The present study showed
that CIL dose dependently reduced the severity of AD-like
skin lesions by decreasing serum IgE and IgG1 levels and
inﬁltration of mast cells and eosinophils in DNCB-treated
NC/Nga mice. The results also indicate that the eﬀects of CIL
were probably due to a decrease in IFN-γ, IL-4, and IL-13
production by activated Th1 and Th2 cells. CIL-High was
f o u n dt ob ea se ﬀective as HC for alleviating AD.
Mast cells are known as key eﬀector cells in IgE-mediated
allergic disorders and are activated by cross-linking of a highEvidence-Based Complementary and Alternative Medicine 7
il-4/β-actin
a
ab
bc
R
e
l
a
t
i
v
e
 
i
n
t
e
n
s
i
t
y
 
o
f
 
m
R
N
A
c∗
†
0
0.2
0.4
0.6
0.8
1
1.2
BG HC
Normal control CIL-low
CIL-high
(a)
IL-13/β-actin
a
a
b
a
ab
b
0
2
4
6
8
10
12
14
16
R
e
l
a
t
i
v
e
 
i
n
t
e
n
s
i
t
y
 
o
f
 
m
R
N
A
IFN-γ/β-actin
b∗
† †
b∗
BG HC
Normal control CIL-low
CIL-high
(b)
Figure 4: IL-4, IL-13, and IFN-γ expression in the dorsal skin.
AD induced in Nc/Nga mice by topical application of 2,4-
dinitrochlorobenzene (DNCB) in the dorsal skin, and a right
ear was topically treated with 1,3-butylen glycol (BG; control),
5% Chrysanthemum indicum L. (CIL-Low), 30% Chrysanthemum
indicum L. (CIL-High), and 0.1% hydrocortisone (HC) on the
lesions for 5 weeks. Normal controls did not have DCNB-induced
AD. After 5 weeks of treatments, total RNA was extracted from the
dorsal skin, and cDNA was generated. The mRNA expression of
IL-4, IL-13, and INF-γ was measured by realtime PCR, and their
relative expression was standardized according to respective β-actin
mRNAlevels.CIL-HighsigniﬁcantlydecreasedtheexpressionofIL-
4, IL-13, and INF-γ in the lesion of the dorsal skin in comparison
to the control and exhibited a statistically similar decrease as HC.
Each value represents the mean ± SD of 5 mice in each group.
∗Signiﬁcantly diﬀerent among the diﬀerent treatments in Nc/Nga
mice at P<0.05. a, b, c Means on the bars with diﬀerent super-
scripts were signiﬁcantly diﬀerent by Tukey test at P<0.05. †Sig-
niﬁcantly diﬀerent between control (BG) and normal control at
P<0.05.
aﬃnity IgE receptor [3]. Upon activation, mast cells undergo
degranulation and release a variety of biologically active
substances, which play an important role in host defense
and allergic reactions including AD. Inﬁltration of mast cells
into the dermis is a necessary characteristic for deﬁning an
appropriate animal model for AD [25]. We investigated the
eﬃcacy of CIL for preventing AD-like skin lesions in DNCB
challenged NC/Nga mice and its mechanism for preventing
and alleviating AD was explored since CIL has been widely
used as an anti-inﬂammatory agent in Southeast Asian folk
medicine. We found that CIL-High signiﬁcantly suppressed
the numbers of mast cells inﬁltrating in the skin lesions of
the atopic dermatitis mice, suggesting that the activation and
migration of mast cells may be an immunopharmacological
target of CIL-High.
It is known that mast cell activation is tightly modulated
by IgE from B cells, and increased total serum IgE levels are a
hallmark of AD [24]. AD induced by DNFB application acti-
vates B cells in NC/Nga mice by a Th2 reaction through IL-4
that elevates IgE production [25]. IgE expression is known
to cause both acute and chronic phase skin symptoms.
Consistent with these reports, we found that serum IgE levels
weresigniﬁcantlyincreasedbyrepeatedDNCBapplicationin
NC/Nga mice, as was IL-4 and IL-13 production by activated
Th2 cells. These cytokines are known to play important roles
in the inﬂammation and hypertrophy of the skin in AD [25].
We also found that higher IgE, IL-4, and IL-13 levels were
associated with more severe skin lesions. Topical application
of CIL-High signiﬁcantly improved the severity of AD-like
skin lesions by suppressing serum IgE, IL-4, and IL-13 levels.
The improvement by CIL-High was as eﬀective as with HC.
In addition to cytokines released from Th2 cells, Th1
cytokines such as INF-γ are involved in AD development
[4]. Under normal conditions, the diﬀerentiation of naive
T cells to Th1 and Th2 lineages is regulated by cytokines
that are secreted from various cells, including themselves,
and the Th1/Th2 balance is maintained [6, 7]. However, in
atopic dermatitis, the balance shifts to Th2 dominance; this
eventually leads to excessive Th2 cytokine production [6].
Some studies have found that increased INF-γ levels alleviate
AD-like symptoms, but those results remain controversial.
In the present study, repeated DNCB application increased
both IFN-γ and IL-4 production from activated CD4+ T
cells of draining lymph nodes in NC/Nga mice. CIL dose
dependently decreased both Th1 (INF-γ) and Th2 cytokines
(IL-4 and IL-13) as eﬀectively as HC. Furthermore, the ratio
of Th1 to Th2 cytokines was increased by CIL treatment.
In conclusion, CIL-High reduced the development of
AD-like skin lesions resulting from repeated DNCB applica-
tion in NC/Nga mice by suppressing total serum IgE levels
and IFN-γ and IL-4 production by activated CD4+ T cells.
CIL-High ameliorated AD symptoms as eﬀectively as HC.
Sesquiterpenes and ﬂavonoids in CIL may be the active
components exerting anti-AD-like eﬀects; further study is
needed to identify the primary active components.
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